> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Gilead Submits NDA for Triple Drug Combo for Hep C
- URL: https://www.fdaweb.com/gilead-submits-nda-for-triple-drug-combo-for-hep-c/
- Published: 2016-12-08T12:00:00.000Z
- Updated: 2026-09-14T21:53:25.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5137521

Gilead Sciences has submitted an NDA for an investigational, once-daily single tablet regimen containing sofosbuvir 400 mg, velpatasvir 100 mg, and voxilaprevir 100 mg (SOF/VEL/VOX) for treating direct-acting antiviral (DAA)-experienced chronic hepatitis C virus (HCV)-infected patients. The submission is based on data from two Phase 3 studies (POLARIS-1 and POLARIS-4), which evaluated 12 weeks of the fixed-dose combination in DAA-experienced patients with hepatitis C genotypes 1-6, including those who failed prior treatment with an NS5A-containing regimen, according to the company. Of the 445 patients treated, 430 (97%) achieved the primary efficacy endpoint, it says. The NDA is further supported by two additional Phase 3 studies (POLARIS-2 and POLARIS-3) in which 611 DAA-naïve HCV-infected patients received eight weeks of SOF/VEL/VOX. The most common adverse events seen in trials were headache, fatigue, diarrhea and nausea.